At the jade processing site, the high-speed milling cutter collided with the raw material violently, and the sparks also aroused dust; At the seaside, the ten thousand ton ship was covered with rust. Young people wearing masks polished it with steel sand, raising scattered dust. These scenes seem to have nothing to do with medical research and development, but in the eyes of Jiang Jiandong, member of the CPPCC National Committee, pharmacologist, and academician of the CAE Member, they are new challenges to health. "The number of potential pneumoconiosis patients in new business forms and new types of work is increasing," said Jiang Jiandong, who said that the continuous development of economy and society has brought new topics to the medical industry. People's health problems are the source of original innovation. How to further stimulate the original power, solve the medical needs of the people, and promote the high-quality development of China's pharmaceutical industry? Representative members bring insights. Research on front-line health problems should not blindly follow the influencing factors of brucellosis in northern pastoral areas, schistosomiasis in southern lakes, AIDS and tuberculosis in large cities in the east... In Jiang Jiandong's view, these are "question banks" of original achievements in the medical field and a great dance platform for scientists. "Medical research cannot be keen on pursuing 'fashion'." Jiang Jiandong said that while we pay attention to the new findings in top journals and analyze their latest ideas and methods, we should pay attention not to blindly follow the influence factors, otherwise it will be farther and farther away from the original. Many people say that there are only a few targets, and I don't know where to start with the development of original drugs. Jiang Jiandong's advice is very simple: go to the scene to investigate, find scientific questions and answers, and don't just search others' papers, deduce and propose topics. "Going to the scene, feeling the pain of patients, the horror of disease, and the urgency of treatment can not only stimulate the enthusiasm for innovation, but also cultivate the sense of responsibility of researchers." Jiang Jiandong said that many times, it has been proved that carrying out research with a sense of responsibility can not only sit on the "cold bench", but also keep the academic bottom line. In the final analysis, the research and development of original drugs will ultimately focus on the human body, cure diseases and face life and health. Optimize the research and development ecology and change the fate of "nine lives". In the process of research and development of original drugs, the risk of "nine lives" is unavoidable. The development of original drugs often requires decades and billions of yuan of investment. Why are there still many projects "broken"? Jiang Jiandong explains the low success rate in this way: on the one hand, the understanding of human body mysteries in modern science is far from enough, on the other hand, the requirements of drug research are very high. There are many variables and long time in the process from "theoretical design" to "becoming a drug", and factors such as the change of disease spectrum, production process, manufacturing cost, environmental protection, clinical actual situation, social environment, and policy changes should also be considered. This is a system engineering with high difficulty and high technology integration. "It is very important to promote the high-quality development of the pharmaceutical industry and improve the success rate of research and development. We should establish a mechanism to tolerate failure." Jiang Jiandong said that letting a hundred flowers bloom and competing for the best is the cultural fertile ground for scientific and technological innovation, and it is the tolerance mechanism that can stimulate original innovation. If the scientific research project management sends the signal that "original research doesn't matter even if it fails", the scientific and technological achievements will shine like stars. Li Yan, a representative of the National People's Congress of pharmaceutical enterprises and president of Qilu Pharmaceutical Group, is more concerned about accelerating the implementation and transformation of achievements by optimizing the research and development ecology. "I